# A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

> **NCT03718299** · PHASE4 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 55 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Injections of tildrakizumab

## Key facts

- **NCT ID:** NCT03718299
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-16
- **Primary completion:** 2021-11-02
- **Final completion:** 2021-11-05
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718299, "A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03718299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*